Silexion Doses First Patient in Phase 2/3 Trial for SIL204

Grand Cayman, Cayman Islands and Ramat Gan, Israel -- Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company specializing in RNA interference therapies for KRAS-driven cancers, has successfully dosed the first patient worldwide in its Phase 2/3 clinical trial. The study evaluates its lead candidate, SIL204, in combination with standard chemotherapy for patients with locally advanced pancreatic cancer (LAPC).

The treatment was administered at the Tel Aviv Sourasky Medical Center in Israel. The trial is designed as a prospective, randomized, multinational study comparing the integrated therapeutic regimen against chemotherapy alone. It initially features a safety run-in cohort of approximately 18 patients, followed by a randomized global expansion cohort of about 166 patients.

Key Highlights

• First patient successfully dosed at Tel Aviv Sourasky Medical Center (Ichilov).
• Phase 2/3 trial evaluates SIL204 combined with standard chemotherapy for LAPC.
• Innovative dual-route delivery combines EUS-guided intratumoral administration with subcutaneous abdominal injections.
• Sites in Israel and Germany are preparing for activation under European clinical trial regulations.